Get notified when RGTI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Chips Act Award Structure And Enforceability (new) — The Department of Commerce has unilateral right to make the Letter of Intent binding if definitive documents are not executed within 90 days due to the company's failure to negotiate in good faith; the company has no reciprocal enforcement right, creating asymmetric contractual risk.
- Equity Dilution Without Guaranteed Capital (new) — Company must issue common stock to the Department at a 15% discount to the lowest closing price among three specified dates; the Department retains 100% of shares regardless of whether the award is fully funded or clawed back.
- Milestone Achievement And Clawback Risk (new) — CHIPS Act funding is contingent on achieving project milestones over a five-year period; failure to meet milestones could result in withheld funding and potential return of previously disbursed amounts.
- Ip And Strategic Flexibility Restrictions (new) — Award imposes 10-year restrictions on ownership transfer of funded inventions and background IP (must remain U.S.-owned) and requires domestic production; definitive award documents will contain covenants restricting strategic actions such as financings, M&A, and asset sales.
- History Of Missed Milestones And Roadmap Changes (worsened) — Company now explicitly discloses a pattern of missing publicly announced milestones and changing its technology roadmap in 2018, 2022, 2023, and 2025, with another roadmap update planned for 2026.
Revenue triples to $5.1M (+185%) on Novera sales; net loss widens 33% to -$52.6M in Q2 2026
Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 12, 2025 · ~2 min read
Key Changes
-
high
Revenue reached $5.1M, up 185.3% YoY, driven by sales of 9-qubit Novera quantum computing systems and related products. Six-month revenue hit $9.5M (up 191%), marking a shift from collaborative research contracts to hardware sales.
MD&A: Revenue verify on EDGAR → -
high
Net loss widened 32.7% to $52.6M ($0.16 per diluted share, down 23.1%) despite operating loss widening 41% to $28.1M.
Key Financials / Notes: Operating Loss verify on EDGAR → -
high
Announced Letter of Intent with U.S. Department of Commerce for up to $100M in CHIPS Act funding, disbursed in milestone-based tranches. Award requires issuing common stock to the Department at a 15% discount; the Department retains all shares even if funding is clawed back.
MD&A: CHIPS Act LOI verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (COTY 10-K) is open in full — no account needed.
Partner
Trade RGTI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 25, 2026 · How we verify